U.S. Markets open in 8 hrs 30 mins

Cyclacel Provides Clinical Development Update and Growth Drivers for 2019 in New SNNLive Video Interview on StockNewsNow.com

LOS ANGELES, CA / ACCESSWIRE / March 26, 2019 / StockNewsNow.com, The Official MicroCap News Source™, today published an SNNLive Video Interview with Spiro Rombotis, President and CEO of Cyclacel Pharmaceuticals, Inc. (CYCC), a biopharmaceutical company developing innovative medicines based on cancer cell biology, according to the company's website (see here: www.cyclacel.com). The video interview was recorded at the BIO CEO & Investor Conference 2019 in New York, NY.

Click the following link to watch the SNNLive Video Interview on StockNewsNow.com:

Cyclacel Pharmaceuticals – Clinical-stage Biopharmaceutical Company Provides Corporate Update, Clinical Development and Growth Drivers

You can follow Stock News Now on FACEBOOK, TWITTER, LINKEDIN, YOUTUBE, and STOCKTWITS

Please review important disclosures on our website at: http://stocknewsnow.com/legal.php#disclaimer

About Cyclacel Pharmaceuticals, Inc.

Cyclacel Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in cell cycle, transcriptional regulation and DNA damage response biology in cancer cells to develop innovative medicines. The transcriptional regulation program is evaluating CYC065, a CDK inhibitor, in patients with advanced solid cancers and in combination with venetoclax in patients with advanced hematological malignancies, including CLL and AML. The DNA damage response program is evaluating a sequential regimen of sapacitabine and seliciclib, a CDK inhibitor, in BRCA positive patients with advanced solid cancers and a concomitant regimen of sapacitabine and olaparib, a PARP inhibitor, in BRCA positive patients with breast cancer. CYC140, a PLK inhibitor, is in a Phase 1 first-in-human study in patients with advanced leukemias. Cyclacel's strategy is to build a diversified biopharmaceutical business focused in hematology and oncology based on a pipeline of novel drug candidates. For additional information, please visit www.cyclacel.com.

About StockNewsNow.com

StockNewsNow.com is a microcap financial news portal that features news and insights from the microcap and emerging growth financial community. StockNewsNow.com is a multimedia destination hub for information about microcap and emerging growth public and private companies, market events, news, bulletins, stock quotes, expert commentary and company profiles that feature SNN-produced video like SNNLive CEO video interviews, as well as their latest news and headlines. Users can engage directly and share the information provided through social media.

Follow the companies YOU want to know more about; read and watch content from YOUR favorite microcap, emerging growth financial experts; register to attend financial conferences of YOUR choosing; find microcap and emerging growth financial professionals that YOU may be looking for - all here on StockNewsNow.com.

StockNewsNow.com

info@stocknewsnow.com

SOURCE: StockNewsNow.com



View source version on accesswire.com:
https://www.accesswire.com/540130/Cyclacel-Provides-Clinical-Development-Update-and-Growth-Drivers-for-2019-in-New-SNNLive-Video-Interview-on-StockNewsNowcom